Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Rheumatol ; 28(6): 849-54, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21122264

RESUMO

OBJECTIVES: Prolactin (PRL) is a hormone with cytokine-like activities that has been demonstrated to be involved in immune responses. However, there are inconsistent results related to the role of PRL in rheumatoid arthritis (RA). Therefore, the aim of this study was to evaluate the levels of PRL in serum and synovial fluid in patients with RA and osteoarthritis (OA) and examine whether PRL might be associated with laboratory and clinical disease activity of RA. METHODS: A total of 29 patients with RA and 26 patients with OA were included in the study. The concentration of PRL in the serum and synovial fluid was measured by immunoradiometric assays, and the levels of serum anti-citrullinated protein/peptide autoantibodies (ACPA) and IgM rheumatoid factor (IgM-RF) were analysed by ELISA. Disease activity score (DAS 28) and radiological (Larsen) score were assessed. RESULTS: The levels of PRL in serum (299.55±27.28 vs. 230.59±16.61 mIU/l, p=0.041) as well as in synovial fluid (338.85±33.49 vs. 245.97±21.88 mIU/l, p=0.024) were significantly higher in patients with RA than in patients with OA. A moderate correlation was found between disease activity of RA and levels of PRL in synovial fluid (r=0.485, p=0.010) and the serum PRL levels correlated significantly with the total Larsen score (r=0.484, p=0.014). CONCLUSIONS: The findings of increased prolactin levels in patients with RA lead to the assumption that prolactin may play a role in disease severity and the process of joint damage in RA.


Assuntos
Artrite Reumatoide/metabolismo , Artrite Reumatoide/patologia , Prolactina/metabolismo , Índice de Gravidade de Doença , Líquido Sinovial/metabolismo , Idoso , Artrite Reumatoide/diagnóstico por imagem , Autoanticorpos/sangue , Feminino , Humanos , Imunoglobulina M/sangue , Articulação do Joelho/diagnóstico por imagem , Articulação do Joelho/patologia , Masculino , Pessoa de Meia-Idade , Osteoartrite do Joelho/diagnóstico por imagem , Osteoartrite do Joelho/metabolismo , Osteoartrite do Joelho/patologia , Radiografia , Fator Reumatoide/sangue
2.
Clin Exp Rheumatol ; 25(4): 540-5, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17888209

RESUMO

OBJECTIVE: To evaluate the clinical status and radiographic progression in patients with rheumatoid arthritis (RA) being followed by the Czech National Registry of biological treatments. METHODS: Patients who failed at least two disease-modifying antirheumatic drugs and had high disease activity (DAS28 > 5.1) were treated with infliximab. Radiographic progression was measured with a modified version of the Sharp score (TSS) after 54 weeks of treatment. RESULTS: Ninety-nine patients with an average disease duration of 13.7 years were enrolled. The DAS28 dropped from 6.66 to 4.07 (p < 0.001). Before treatment the mean TSS was 90.1 and the mean estimated yearly disease progression was 8.56. After 54 weeks of infliximab, radiographic progression was 4.15 times slower than the estimated rate before treatment and 63 patients did not show any radiographic progression at all. In the remaining 36 patients, the progression rate slowed to 3.8 +/- 0.9 from the estimated TSS of 10.9 +/- 6.9 before the initiation of treatment (p = 0.011). CONCLUSION: Data derived from the Czech National Registry, which reflect general clinical practice, show a significant retardation of radiographic progression in patients treated with anti-TNF and the magnitude of the improvement seen is similar to results from clinical trials.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/diagnóstico por imagem , Artrite Reumatoide/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , República Tcheca , Progressão da Doença , Feminino , Humanos , Infliximab , Masculino , Pessoa de Meia-Idade , Radiografia , Sistema de Registros
3.
Rheumatology (Oxford) ; 46(7): 1174-9, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17500079

RESUMO

OBJECTIVES: Acute inflammation in idiopathic inflammatory myopathies (IIM) causes oedema that can be visualized by magnetic resonance imaging (MRI). The inflammatory infiltrate in IIM is thought to be frequently in a focal distribution. The aim of this study is to better evaluate the relationship of MR image of thigh muscles to clinical and histological parameters in patients with IIM. METHODS: MRI-short tau inversion recovery (STIR) technique was used to distinguish between affected and non-affected muscles. Computer tomography (CT)-controlled targeted needle biopsy was used for sampling. The intensity of muscle oedema, its extent and total assessment on MRI were evaluated with 10 cm visual analogue scale. The intensity of inflammatory infiltrate was assessed using 5-point grading system. The second MRI and muscle biopsy were performed after the time interval of treatment. RESULTS: MR scans, muscle biopsy and clinical examination were performed in 29 patients with polymyositis (PM) and dermatomyositis (DM). Paired MRI-affected and MRI-non-affected biopsy samples were obtained from 17 cases. In six cases, the biopsy was available for comparison before and after period of treatment. At the initial examination, it was the intensity of oedema on MRI that was associated with clinical status. Mean intensity of MRI findings significantly decreased in 10 patients where the MRI was available also after treatment. The mean intensity of inflammatory infiltrate in PM/DM patients was 2.5 +/- 0.7 for MRI-affected and 1.7 +/- 0.6 for MRI-non-affected muscles (P < 0.001). Mean intensity of inflammatory infiltrate in the MRI-affected muscles in the first examination (n = 6) was 2.2 +/- 0.8 and did not significantly decrease in the second examination in samples taken after the treatment (2.0 +/- 0.9). CONCLUSION: It is mainly the signal intensity in MR scan, which is associated with disease activity in the acute presentation of PM/DM. Muscle biopsy guided by positive MRI finding contains significantly more inflammatory cells than the biopsy taken from MRI non-affected sites. However, even in parts of muscles, which look unaffected on MR scan, the inflammatory cells can be found. The intensity on MR scans decreases significantly after the treatment, but the histologically detected inflammation does not change substantially.


Assuntos
Imageamento por Ressonância Magnética , Polimiosite/diagnóstico , Adulto , Idoso , Biópsia por Agulha/métodos , Dermatomiosite/diagnóstico , Dermatomiosite/patologia , Dermatomiosite/fisiopatologia , Edema/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/patologia , Músculo Esquelético/fisiopatologia , Polimiosite/patologia , Polimiosite/fisiopatologia , Tomografia Computadorizada por Raios X , Resultado do Tratamento
4.
Vnitr Lek ; 48(5): 403-8, 2002 May.
Artigo em Tcheco | MEDLINE | ID: mdl-12061207

RESUMO

In the submitted review the author analyzes the ratio, function and role of two different forms of cyclooxygenases--cyclooxygenase type 1 and cyclooxygenase type 2--in the human organism. Special attention is devoted to specific inhibitors of cyclooxygenase type 2. Specific inhibition of COX-2 is associated with a lower incidence of undesirable reactions while the antiinflammatory and analgetic effect is preserved. Celecoxib and rofecoxib--the oldest representatives of drugs from this group were used in a number of clinical studies. The results of some of these studies are presented and commented.


Assuntos
Inibidores de Ciclo-Oxigenase/uso terapêutico , Isoenzimas/antagonistas & inibidores , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Celecoxib , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/efeitos adversos , Humanos , Isoenzimas/fisiologia , Lactonas/efeitos adversos , Lactonas/uso terapêutico , Proteínas de Membrana , Prostaglandina-Endoperóxido Sintases/fisiologia , Pirazóis , Sulfonamidas/efeitos adversos , Sulfonamidas/uso terapêutico , Sulfonas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...